Rachel K. King
CIK 1589712 · President, CEO · last filed 2025-06-30
Rachel K. King is a President, CEO who has filed 34 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for FULC, was dated Jun 30, 2025. Across all open-market trades the lifetime net is −$223.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $233.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$233.5K
3
34
-$223.3K
Holdings By Company
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-30 | FULC | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | NVAX | Exer (M) | +10,420 | $0 | EDGAR |
| 2025-01-02 | NVAX | Sell (S) | −4,150 | -$37.4K | EDGAR |
| 2024-11-14 | FULC | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | NVAX | Mixed | +6,670 | $0 | EDGAR |
| 2024-05-01 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +3,334 | $10.0K | EDGAR |
| 2024-01-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +4,238 | $10.0K | EDGAR |
| 2023-10-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +6,667 | $10.0K | EDGAR |